Search results
Zealand Pharma AS (ZEAL) Stock Jumps 9.1%: Will It Continue to Soar?
Zacks via Yahoo Finance· 2 years agoZealand Pharma AS (ZEAL) witnessed a jump in share price last session on above-average trading...
Recent Price Trend in Zealand Pharma A/S (ZLDPF) is Your Friend, Here's Why
Zacks via Yahoo Finance· 11 months agoZealand Pharma A/S (ZLDPF) made it through our "Recent Price Strength" screen and could be a great...
Zealand Pharma, Novo Nordisk Ink Licensing Pact For Drug To Lower Blood Sugar Levels
Benzinga via Yahoo Finance· 2 years agoZealand Pharma A/S (NASDAQ: ZEAL) has entered into a global license and development agreement with...
Zealand Pharma's Dasiglucagon Aces Late-Stage Study In Pediatric Patients, Shares Move Higher
Benzinga via Yahoo Finance· 2 years agoZealand Pharma A/S (NASDAQ: ZEAL) has announced topline results from its second Phase 3 trial of...
Zealand Pharma Amends Financing Agreement With Oberland Capital
Benzinga via Yahoo Finance· 2 years agoZealand Pharma A/S (NASDAQ: ZEAL) has amended its existing financing agreement with Oberland Capital...
7 Sorry Pharma Stocks to Sell in April Before It’s Too Late
InvestorPlace via Yahoo Finance· 1 year agoFinding the best pharma stocks to sell can be an all-or-nothing kind of business. If you score on a...
Is It Too Late to Buy Viking Therapeutics Stock?
Motley Fool via Yahoo Finance· 1 month agoViking Therapeutics (NASDAQ: VKTX) has emerged this year as a formidable contender in the increasingly popular anti-obesity market. While it doesn't have...
Stock Market Rally At Highs After Big Earnings, Inflation Data: Weekly Review
Investor's Business Daily· 2 months agoThe major indexes were narrowly mixed, holding at or near record highs, while the small-cap Russell...
Lumos Pharma (LUMO) Reports Q2 Loss, Tops Revenue Estimates
Zacks via Yahoo Finance· 9 months agoLumos (LUMO) delivered earnings and revenue surprises of -2.83% and 6.25%, respectively, for the...
Verve Stock Soars On $250 Million Eli Lilly Deal
Investor's Business Daily· 6 months agoPharma behemoth Eli Lilly will pay $250 million upfront for the rights to three gene-editing drugs from Verve Therapeutics, the companies said Tuesday....
